PF 614
Alternative Names: BIO-MD™ PF614; ER Oxycodone - Ensysce Biosciences; ER Oxycodone Bio-MD™ System; Oxycodone prodrug extended release - Ensysce Biosciences; PF614; PF614-TAAP™; PRF 06014; PRF-06104Latest Information Update: 26 Mar 2025
At a glance
- Originator PharmacoFore
- Developer Ensysce Biosciences
- Class Alkaloids; Morphine derivatives; Opioid analgesics; Small molecules
- Mechanism of Action Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pain
Most Recent Events
- 10 Mar 2025 Ensysce Biosciences announces intention to submit NDA to US FDA for Pain in 2026
- 24 Nov 2024 Ensysce Biosciences initiates a phase I trial for Pain (In volunteers) in USA (PO, capsule) (NCT06500793)
- 02 Oct 2024 Ensysce Biosciences plans a phase III trial for Postoperative pain (PO) in March 2025 (NCT06602271)